GNI Group has agreed to acquire 100% of Ayumi Pharmaceutical Holdings from shareholders led by Blackstone for about ¥44.8 billion. This acquisition significantly expands GNI's commercial footprint in Japan, especially in pain management and rheumatology, and is expected to increase combined fiscal 2026 revenue to around ¥65.2 billion. Ayumi's flagship product Calonal® dominates Japan's acetaminophen market, and the deal enhances GNI's ability to introduce innovative therapies and biosimilars in Japan. The acquisition also diversifies GNI's geographic revenue base and strengthens its financial stability for future growth.
The funding rate for Bitcoin perpetual futures on OKX has plunged to an extreme annualized -453%, forcing short sellers to pay about 1.3% daily just to hold their positions. This unusually high negative rate indicates a heavy concentration of short b...
The Wegovy pill, a GLP-1 weight-loss medication by Novo Nordisk, has surpassed 3 million prescriptions in the US since its launch on January 5, 2026. This equates to one prescription filled every five seconds, marking it as one of the most successful...
Everest Medicines has acquired the rights from Corxel Pharmaceuticals to develop, manufacture, and commercialize VIZZ (LNZ100), an aceclidine-based eye drop for presbyopia, in Greater China. The drug's New Drug Application was submitted in China in S...
Morpho Midnight is a new DeFi lending protocol offering fixed-rate loans with set maturity dates, replacing traditional floating-rate models. It pools liquidity across markets sharing the same end date to prevent fragmentation and allows lenders to k...
Bitcoin rose above $61,800, with Ethereum outperforming by gaining over 4%, signaling a modest risk-on shift in the crypto market. Several major altcoins also saw gains, indicating improving sentiment beyond Bitcoin. However, trading volumes across s...
